Literature DB >> 8458388

Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth.

S Krüger-Krasagakes1, W Li, G Richter, T Diamantstein, T Blankenstein.   

Abstract

Tumor-associated eosinophils have been observed in human tumors and in experimental tumor models, but their function is poorly understood. To study the role of eosinophils during tumor growth, the plasmacytoma J558L and the mammary adenocarcinoma TS/A were transfected with an expression vector encoding the murine gene for interleukin-5 (IL-5), a cytokine inducing proliferation and activation of eosinophils. Injection of parental cells, mock-transfectants and IL-5-producing cells into syngeneic mice showed that local IL-5 secretion induced rapid tumor infiltration by eosinophils, as evidenced by immunohistochemical staining, but nevertheless did not alter the tumor growth kinetics of IL-5 transfectants. Therefore, the mere presence of IL-5 and eosinophils was not sufficient to induce a protective host immune response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458388     DOI: 10.1002/eji.1830230438

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

2.  Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth.

Authors:  S Pacor; R Gagliardi; P Spessotto; G Zabucchi; G Sava
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 3.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

4.  Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1.

Authors:  Pearline Zhaoying Teo; Paul J Utz; Joseph A Mollick
Journal:  Cancer Immunol Immunother       Date:  2012-06-13       Impact factor: 6.968

5.  Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response.

Authors:  Stephania A Cormier; Anna G Taranova; Carrie Bedient; Thanh Nguyen; Cheryl Protheroe; Ralph Pero; Dawn Dimina; Sergei I Ochkur; Katie O'Neill; Dana Colbert; Theresa R Lombari; Stephanie Constant; Michael P McGarry; James J Lee; Nancy A Lee
Journal:  J Leukoc Biol       Date:  2006-04-14       Impact factor: 4.962

6.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Authors:  Rafael Carretero; Ibrahim M Sektioglu; Natalio Garbi; Oscar C Salgado; Philipp Beckhove; Günter J Hämmerling
Journal:  Nat Immunol       Date:  2015-04-27       Impact factor: 25.606

7.  Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice.

Authors:  Michael Samoszuk; Tom Deng; Mark J Hamamura; Min-Ying Su; Nicholas Asbrock; Orhan Nalcioglu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells.

Authors:  Y Masuda; S Mita; K Sakamoto; T Ishiko; M Ogawa
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

9.  Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

Authors:  L Gabriele; T Kaido; D Woodrow; J Moss; M Ferrantini; E Proletti; L Santodonato; C Rozera; C Maury; F Belardelli
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

Review 10.  Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.

Authors:  Carla De Giovanni; Giordano Nicoletti; Lorena Landuzzi; Arianna Palladini; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.